Attar, Armin http://orcid.org/0000-0002-4133-4870
Farjoud Kouhanjani, Mohsen
Hessami, Kamran
Vosough, Massoud
Kojuri, Javad
Ramzi, Mani
Hosseini, Seyed Ali
Faghih, Marjan
Monabati, Ahmad
Clinical trials referenced in this document:
Documents that mention this clinical trial
Effect of once versus twice intracoronary injection of allogeneic-derived mesenchymal stromal cells after acute myocardial infarction: BOOSTER-TAHA7 randomized clinical trial
https://doi.org/10.1186/s13287-023-03495-1
Funding for this research was provided by:
Ministry of Health and Medical Education
Vice-Chancellor for Research, Shiraz University of Medical Sciences (SG-98-5, SG-98-94, SG-96-86)
Article History
Received: 9 April 2023
Accepted: 12 September 2023
First Online: 23 September 2023
Change Date: 14 February 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13287-024-03663-x
Declarations
:
: The Ethics Committee of Shiraz University of Medical Sciences approved the study protocol titled “Comparing the effects of once versus twice intracoronary injection of allogeneic-derived mesenchymal stem cells in improving ejection fraction of patients with post-myocardial infarction moderate to severe reduced ejection fraction” on 20/06/2020 under Approval Number IR.SUMS.REC.1399.406. All participants provided written informed consent, and all study procedures were carried out in line with the Declaration of Helsinki.
: Not applicable.
: MV is the regulatory affairs manager at CellTech Pharmed. He has no shares in the company. All other authors have nothing to declare.